Birth-genome screening could reshape early childhood care
Global genomic newborn-screening studies (eg, GUARDIAN, BabyScreen+, BabyDetect) are testing broad sequencing on dried-blood spots to flag treatable conditions not covered by traditional panels. Early results suggest confirmable findings in about 1–3% of infants, with some cases prompting life-saving interventions like bone-marrow transplants and earlier seizure treatment. While promising, researchers and ethicists debate cost, scalability, which genes/conditions to include, how to report results, and the potential for privacy or discrimination, as families’ experiences with counseling and communication vary.